Literature DB >> 18369085

Lipid abnormalities and cardiovascular risk in renal disease.

Eberhard Ritz1, Christoph Wanner.   

Abstract

The recent 4D study failed to provide definitive evidence for benefit of statin use in type 2 diabetics on dialysis. This finding stands in stark contrast to a number of other observations in patients with early stages of chronic kidney disease where substantial benefit of statins had been documented. Here we discuss some potential explanations for the unexpected finding of the 4D study and for the negative association between below average total cholesterol and vascular mortality among dialysis patients. Admittedly, in the absence of definite evidence in dialysis patients, we still conclude that the administration of statins is appropriate in patients with manifest coronary disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18369085     DOI: 10.1681/ASN.2007101128

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  9 in total

Review 1.  Treatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins.

Authors:  Roberto Scarpioni; Marco Ricardi; Vittorio Albertazzi; Luigi Melfa
Journal:  World J Nephrol       Date:  2012-12-06

2.  Rosuvastatin in diabetic hemodialysis patients.

Authors:  Hallvard Holdaas; Ingar Holme; Roland E Schmieder; Alan G Jardine; Faiez Zannad; Gudrun E Norby; Bengt C Fellström
Journal:  J Am Soc Nephrol       Date:  2011-05-12       Impact factor: 10.121

Review 3.  Atherosclerotic-nephropathy: an updated narrative review.

Authors:  Mariadelina Simeoni; Silvio Borrelli; Carlo Garofalo; Giorgio Fuiano; Ciro Esposito; Alessandro Comi; Michele Provenzano
Journal:  J Nephrol       Date:  2020-04-08       Impact factor: 3.902

4.  Serum triglycerides and risk for death in Stage 3 and Stage 4 chronic kidney disease.

Authors:  Sankar D Navaneethan; Jesse D Schold; Susana Arrigain; George Thomas; Stacey E Jolly; Emilio D Poggio; Martin J Schreiber; Mark J Sarnak; Joseph V Nally
Journal:  Nephrol Dial Transplant       Date:  2012-05-02       Impact factor: 5.992

5.  White adipose tissue overproduces the lipid-mobilizing factor zinc α2-glycoprotein in chronic kidney disease.

Authors:  Caroline C Pelletier; Laetitia Koppe; Marine L Croze; Emilie Kalbacher; Roxane E Vella; Fitsum Guebre-Egziabher; Alain Géloën; Lionel Badet; Denis Fouque; Christophe O Soulage
Journal:  Kidney Int       Date:  2013-02-20       Impact factor: 10.612

6.  Dyslipidemia and risk of renal replacement therapy or death in incident pre-dialysis patients.

Authors:  Pauline W M Voskamp; Merel van Diepen; Friedo W Dekker; Ellen K Hoogeveen
Journal:  Sci Rep       Date:  2018-02-15       Impact factor: 4.379

7.  Perirenal fat thickness is associated with metabolic risk factors in patients with chronic kidney disease.

Authors:  Luis D'Marco; Juan Salazar; Marie Cortez; María Salazar; Marjorie Wettel; Marcos Lima-Martínez; Edward Rojas; Willy Roque; Valmore Bermúdez
Journal:  Kidney Res Clin Pract       Date:  2019-09-30

8.  Dual PPAR α / γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia.

Authors:  O Samuelsson; P O Attman; I Gause-Nilsson; M K Svensson; P Alaupovic
Journal:  PPAR Res       Date:  2013-03-28       Impact factor: 4.964

9.  Glucose Serum Concentrations and Cardiovascular Disease in Patients on the End Stage of Renal Disease without Diabetes Mellitus.

Authors:  Vaia D Raikou; Despina Kyriaki
Journal:  J Cardiovasc Dev Dis       Date:  2015-04-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.